- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV vaccine
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- RSV Respiratory Syncytial Virus
- Interventions
- AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT vaccine, dTpa vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Beaumont, Texas
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Hialeah, Florida • Savannah, Georgia + 8 more
- Conditions
- Healthy Participants
- Interventions
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
- Conditions
- Healthy Participants
- Interventions
- IVX-A12, Licensed RSV Vaccine
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more
- Conditions
- Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
- Interventions
- Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more